DOCSLIB.ORG

DITEP Presentation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

DITEP 2018 01 � Gustave Roussy is one of the largest phase 1 centre, with more than 450 patients included per year in phase 1 trials. The mission of the DITEP is to accelerate the development of new anticancer drugs, to build an ambitious cancer research program (precision medicine, immunotherapy and new targets), and also to give a new hope to patients facing cancer battles. � Dr. Christophe Massard Head of DITEP 3 OUR STRATEGIC VISION AND MISSIONS Created on September 1st, 2013 to strengthen the therapeutic innovation and the early clinical trials at Gustave Roussy. In 2018, this medical department carries the ambition to be one of the top international players in early drug development, precision medicine and immunotherapy. OUR STRATEGIC VISION AND MISSIONS Created on September 1st, 2013 to strengthen the therapeutic innovation and the early clinical trials at Gustave Roussy. In 2018, this medical department carries the ambition to be one of the top international players in early drug development, precision medicine and immunotherapy. Oncology has become in the last decade an exciting therapeutic area bridging new scientific concepts and major clinical breakthroughs for the patients and their families. Our ambition is to foster a new era of cancer care and treatments by: Promoting innovation and multidiscipli- Continuously developing the medico- nary collaborations to achieve higher scientific expertise of our investigators rates of treatment efficacy based on team and the skills and performance streamlined molecular analyses and of our clinical operations staff through predictive tools generated from our fruitful collaborations and partnerships precision medicine programs, as well with pharma and biotech companies. as innovative imaging methods. Pursuing our quality assurance Facilitating patients’ inclusion in phase management in the context of ISO- I/II studies at an earlier stage of the 9001 certification. disease to acknowledge the early clinical trial as a true therapeutic opportunity within an integrated cancer care management structure. Positioning cancer immunotherapy and the novel immunomodulators as early as possible as potential backbone therapies for combinations with other approaches. OVERALL ORGANIZATION OF THE DITEP DITEP KEY STEPS September 2006 Early drug development and clinical trials identified as a strategic orientation of Gustave Roussy. Prof Soria appointed as the leader of a working group for therapeutic innovation and early clinical trials expansion. September 2007 Establishment of the early clinical trial pluridisciplinary committee (RCP-150) September 2008 Creation of the « SITEP » (Service des Innovations Thérapeutiques et Essais Précoces), first hospitalization unit in France fully dedicated to early clinical trials in oncology (first-in-human administration, phase I trials, phase October 2010 I/II extension cohorts) with 8 beds and 6 out- patient seats. Recognition granted by the french National Cancer Institute (INCA, 4 years) of SITEP as an early trials center (CLIP²) July 2011 Certification of the french Health Regional Agency (ARS, 5 years) for first-in-human trials September 2013 Creation of the DITEP as a full medical department of Gustave Roussy , headed DITEP Drug Development Department by Prof. Soria. February 2015 Renewal of the CLIP² label by INCA (4 years) May 2015 New premises gathering all the DITEP teams on one floor (4th) September 2016 Renewal of the ARS certification for first-in-human trials November 2016 ISO 9001 accreditation N°2016/72604.1 September 2017 Dr Massard appointed as Head of the DITEP Headed by Dr. Christophe Massard, in 2018 the DITEP encompasses 150 full-time equivalents dedicated to early clinical trials, translational research and precision medicine programs. Since November 2016, the DITEP has obtained the ISO 9001v2015 certification (Quality Management System) for its activities of access to therapeutic innovations, management of early clinical trials, and scientific outreach. MEDICAL AND CLINICAL OPERATION TEAMS • Principal investigators and sub-investigators: 6 MD-PhD, 7 MDs (see CV p.28-40) • Medical and academic assistants & Managers: 13 • Clinical research nurses & Managers: 40 • Head of clinical operation unit: 1 • CRA managers: 2 • Project managers: 7 • Study coordinators: 26 • Clinical research technicians & sample managers: 17 • Schedulers: 3 • Medical research assistants & helpers: 7 • Quality assurance: 1 • Administrative & contracting: 3 • Chief scientific officer: 1 PLURIDISCIPLINARY CLINICAL RESEARCH AND DECISION-MAKING COMMITTEES • The early clinical trial multi-disciplinary tumor board (RCP-150), headed by Dr Vincent Ribrag, encompasses all DITEP experts in medical oncology, radiotherapy, hematology, immunotherapy, as well as experts in biopathology and imaging. This weekly committee is in charge of the validation of all patients’ referral to our phase I programs, and for the review of all on-going trials and medical decisions regarding any complex situations of safety or experimental treatment decisions. • The molecular pluridisciplinary committee (RCPM-150), dedicated to the weekly review of the molecular tumor profiles performed within our precision medicine programs aims at including each phase I-eligible patient in the most adapted clinical trial based on actionable molecular abnormalities. • A monthly Protocol Review Committee (PRC) to address the scientific value and feasibility of new trials proposals. CARE WARDS & FACILITIES • A conventional week-hospitalization unit (4th floor) headed by Dr Antoine Hollebecque: 13 single-patient beds. This unit receives patients who require full-time hospitalization as per protocol or for safety surveillance due to side effects over the week. • An out-patient care unit (4th floor) headed by Dr Andrea Varga: 16 armchairs (whose 2 dedicated to PK). This outpatient unit is operational every day from Monday to Friday from 7:00 am to 7:00 pm (including PK sampling on Saturdays). This unit also receives patients who require nursing and related cares. • A consultation platform facility • An early phase clinical operations unit (4th floor) headed by Mrs Guylène Chartier gathering all staff in the same new premises that host all MDs offices, a local laboratory dedicated to the processing of biological samples, as well as confidential monitoring spaces dedicated to the trials sponsors. 09 ORGANIZATION CHART Head of Department Dr A. Marabelle - Clinical Director of the Cancer Immunotherapy Program functional link Dr E.Angevin - Industrial Partnerships Alliance Manager. Dr. C. Massard Dr J.P.Armand - Senior scientific consultant. Pr E.Deutsch - Head of Radiotherapy Department. Dr V.Ribrag - Head of Early Drug Development multidisciplinary tumor board Dr S. Postel-Vinay - Physician Senior Scientist (UMR 981) functional link Principal Academic functional link External consultant assistant J.Florance B.Thuillier 2 academic assistants Head of early phase Executive Head of medical Head of Head of outpatient Clinical care Clinical care clinical operations unit Assistant secretary hospitalization unit care unit coordinator coordinator QA officer Manager P. Dielenseger G. Bernal- E. Netzer G. Chartier D. Aubry K. Willinger Dr A. Hollebecque Dr A. Varga Trinel 1 Head nurse DITEP 26 study-co 1 principal MA Dr A.Gazzah (day) Dr R.Bahleda 1 Head 2 CRA managers S. Orange Dr J.M.Michot S.Rodrigues nurse 10 data-managers Dr S. Champiat Dr C. Baldini (night) M.Houssaini 5 MA H. Zouhri 5 Sample managers + 25 nurses N. Meunier 2 Medical 1 assistant Administrative KEY FIGURES 1 Contract and Finance manager Secretaries 4 Nurse 7 nurses 1 Finance coordinator + helpers (night) L. Daley 1 Contract coordinator 1 professional training contract 1 Operations 4 Medical clinical Abbreviations coordinator research assistants S. Lancereau + 3 helpers AMR MA : Medical Assistant QA : Quality Assurance 3 schedulers EP : Early Phase 2 project managers CR : Clinical Research in personalized CRA : Clinical Research Associate medecine 2 Data Managers M. Ngo Camus C. Nicotra 1 project manager in Immunotherapy S. Fahrane 5 industrial partnerships project managers F.Colame N. Imam E. Toubiwou E. Zedouard H. Pousse 1 Chief Scientific Officer N. Hainault DITEP KEY FIGURES 2017 KEY FIGURES 3.946stays (Conventional Hospital and Day Hospital) 3.504 medical consultations 34 publications on early clinical trials results and precision medicine programs 11,2as the average journal Impact Factor 2.080 patient’s referrals for inclusion in early clinical trials 104 early clinical trials opened for inclusions 460 patients recruited in early clinical trials 806 patients recruited in precision medicine programs MAIN ACTIVITY INDICATORS Yearly number of ongoing early clinical trials 104 100 96 91 90 88 80 70 70 68 60 55 50 41 40 30 20 10 0 20102011 2012 2013 2014 2015 2016 2017 Early clinical trials, as of January 2018 (in dose escalation and in organ-oriented extension cohorts) 8 3 Other Cell cycle & Apoptosis 6 Epigenetic & metabolic Inhibitors 41 86 Immune Checkpoints 10 & Immunomodulators Antibody Drug Conjugates EARLY CLINICAL & Bispecific Monoclonal TRIALS Antibodies 18 Tyrosine Kinase Inhibitors 13 Patients recruited in DITEP trials 1000 1266 932 900 863 800 757 700 647 600 519 500 460 444 410 443 400 385 344 336 345 300 279 278 200 100 0 2010 2011 2012 2013 2014 2015 2016 2017 Patients recruited in our studies (early clinical trials and precision medicine programs) Patients treated in our early clinical trials (inclusions in our precision medicine programs
Recommended publications
  • Program and the Book of Abstracts BES 2021

    Program and the Book of Abstracts BES 2021

    XXVIth International Symposium on Bioelectrochemistry and Bioenergetics Program of the XXVIth International Symposium on Bioelectrochemistry and Bioenergetics of the Bioelectrochemical Society Online 9-13 May, 2021 Cluj-Napoca, Romania 1 XXVIth International Symposium on Bioelectrochemistry and Bioenergetics The Bioelectrochemical Society Chemin du Closelet 2 1006 Lausanne Switzerland Copyright © 2021 All rights reserved. No part of this work may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Printed in Romania 2 XXVIth International Symposium on Bioelectrochemistry and Bioenergetics Organising Committee Chair: Robert Săndulescu, Iuliu Hațieganu University, Cluj-Napoca, Romania Lo Gorton, Lund University, Sweden Elisabeth Lojou, Marseille University, France Camelia Bala, University of Bucharest, Romania Cecilia Cristea, Iuliu Hațieganu University, Cluj-Napoca, Romania Victor Diculescu, National Institute of Materials Physics, Bucharest Graziella Turdean, Babeș-Bolyai University, Cluj-Napoca, Romania Eleonora-Mihaela Ungureanu, Politehnica University Bucharest, Romania Local Organising Committee Ede Bodoki, Iuliu Hatieganu
  • Killer Yeast: Gastronomic Conspiracy Theories And

    Killer Yeast: Gastronomic Conspiracy Theories And

    FORUM FOR ANTHROPOLOGY AND CULTURE, 2016, NO. 12 KILLER YEAST: GASTRONOMIC CONSPIRACY THEORIES AND THE CULTURE OF MISTRUST IN MODERN RUSSIA Jeanne Kormina National Research University Higher School of Economics 16 Soyuza Pechatnikov Str., St Petersburg, Russia [email protected] A b s t r a c t: This article focuses on gastronomic fears that have spread in contemporary Russia within last decade, or more specifi cally, fears associated with the consumption of yeast bread. Shared by various social groups, from Orthodox fundamentalists to New Age sympathisers and secular middle class people, these social fears reveal the existence of a new culture of distrust in post-Soviet society. The object of distrust is represented by the State along with its institutions responsible for the production and control of knowledge, including science, medicine, education and the mass media. At the same time, the main object of fear is a loss of personal freedom, which is articulated as quality of life, health issues, and opportunities for self-improvement. This article argues that the culture of distrust is a by-product of an information society where instead of having limited access to information from mass-media, people question its accuracy, and have to defi ne or re-defi ne the criteria of its accuracy in their everyday routine. At the same time, the proliferation of the culture of distrust is a reaction to ‘risk situations’ (U. Beck) where the concept of risk is connected with the diversifi cation of knowledge in modern society which leaves customers incapable of estimating the level of threat that invisible and omnipresent enemies, like GMOs or yeasts, present.
  • Advancing Public Awareness

    Advancing Public Awareness

    Advancing public awareness SCIENCE FOR CONSERVATION: 27 John Pettigrew Published by Department of Conservation P.O. Box 10-420 Wellington, New Zealand Science for Conservation presents the results of investigations contracted to science providers ourside the Department of Conservation. Reports are subject to peer review within the Department and, in some instances, to a review from outside both the Department and the science providers. © May 1996, Department of Conservation ISSN 1173-2946 ISBN 0-478-01789-8 This publication originated from work done under Department of Conservation contract 1843/1844 carried out by John Pettigrew, 14 Fairview Cescent Wellington. It was approved for publication by the Director, Science and Research Division, Department of Conservation, Wellington. Cataloguing-in-Publication data Pettigrew, John Advancing public awareness /John Pettigrew. Wellington, N.Z. Dept. of Conservation, 1996. 1 v. ; 30 cm. (Science for conservation, 1173-2946 ; 27) Includes bibliographical references. ISBN 0478017898 1. Conservation of natural resources--New Zealand--Public opinion. 2. Conservation of natural resources--New Zealand--Citizen participation. 3. Public opinion--New Zealand. I. Title. 11. Series: Science for conservation; 27 333.70993 20 zbn96-044007 CONTENTS Preface 5 Abstract 1. Introduction 1.1 Objectives 1.2 Applicability of findings 7 1.3 References 8 2. Conceptual structures 8 2.1 The flow of communications 8 2.2 Agenda setting and attitude modification 9 2.3 Degrees of impact - little, much, or complex 10 2.4 Overall picture 10 3. Media effects 11 3.1 Broadcast vs print - opportunity to respond 11 3.2 Mass, quasi-mass, and personal 12 3.3 Media ownership and control 12 3.4 Television 13 3.5 Newspapers and magazines 14 3.6 Small media - leaflets 14 3.7 Interpersonal communications 16 4.
  • Safe Management of Wastes from Health-Care Activities

    Safe Management of Wastes from Health-Care Activities

    Contents Safe management of wastes from health-care activities i Safe management of wastes from health-care activities ii Contents Safe management of wastes from health-care activities Edited by A. Prüss Department of Protection of the Human Environment World Health Organization Geneva, Switzerland E. Giroult Ministry of Urban Development and Housing Paris, France P. Rushbrook WHO European Centre for Environment and Health Rome, Italy World Health Organization Geneva 1999 iii Safe management of wastes from health-care activities WHO Library Cataloguing-in-Publication Data Safe management of wastes from health-care activities/edited by A. Prüss, E. Giroult, P. Rushbrook. 1.Medical waste 2.Medical waste disposal—methods 3.Safety management— handbooks 4.Manuals 5.Guidelines I.Prüss, Annette II.Giroult, Eric III.Rushbrook, Philip ISBN 92 4 154525 9 (NLM classification: WA 790) The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed to the Office of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available. © World Health Organization, 1999 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
  • Poster Session

    Poster Session

    POSTER SESSION POSTER SESSION P-1 A Comparative Study of Sample Preparation Methods for 2D PAGE Analysis of Plant Tissue S. C. Carpentier, B. Panis and R. Swennen K.U.Leuven Department of Applied Plant Sciences, Laboratory of Tropical Crop Improvement, Leuven Belgium More and more genomes are being sequenced thereby generating a lot of useful information. Proteomics is seen as a necessary complement between the genomic sequence information and the actual protein population of a specific tissue, cell or cellular compartment. Post- translational modifications - critical for the understanding of the physiological protein function - can not be analysed based on nucleic acid sequences and changes in mRNA transcript levels do not automatically imply corresponding changes in protein amount or activity. Appropriate sample preparation is still one of the most critical steps in 2D electrophoresis and is absolutely essential for good results. Plant material does not provide a ready source of proteins for investigation by 2 D gel electrophoresis. Plant cells generally have a low protein content and contain high concentrations of proteases and other interfering compounds (e.g. salts, organic acids, phenolics, lignins, pigments, terpenes, etc…). Usually, sample preparation involves the removal of non-protein sample components, the complete dissociation of protein interactions and arrest of protease activity. The plant species under investigation, Musa spp (banana), is known to be exceptionally rich in polyphenolic compounds. Four different approaches were tested to extract total proteins: the common method TCA precipitation in acetone (i) without and (ii) with fractionation, (iii) extraction with phenol followed by precipitation with ammonium acetate and (iv) a no-precipitation extraction procedure with fractionation.
  • Protocol for Protocol Amendment # To

    Protocol for Protocol Amendment # To

    SUMMARY OF CHANGES – Protocol For Protocol Amendment # to: NCI Protocol #: 9620 Local Protocol #: CABONE NCI Version Date: 04/04/2019 Protocol Date: 04/04/2019 Please provide a list of changes from the previous CTEP approved version of the protocol. The list shall identify by page and section each change made to a protocol document with hyperlinks to the section in the protocol document. All changes shall be described in a point-by-point format (i.e., Page 3, section 1.2, replace ‘xyz’ and insert ‘abc’). When appropriate, a brief justification for the change should be included. As requested by your request for Amendment, protocol has been updated. # Section Comments Protocol 1) New Protocol Amendment/Version Date Included on the Title/Cover Page per Operations 1. Office Policy: Protocol Cover Page: Page Number(s): 5 Version Date: 04/04/2019 2) Revision of the Protocol CAEPR: 2. Section 7.1 Protocol Section(s) for Insertion of Revised CAEPR (Version 2.4, December 17, 2018): 7.1 Page Number(s): 54 • The SPEER grades have been updated. • The section below utilizes CTCAE 5.0 language unless otherwise noted. • Added New Risk: • Also Reported on XL184 Trials But With Insufficient Evidence for Attribution: Anal mucositis; Atrioventricular block complete; Budd-Chiari syndrome; Cardiac disorders - Other (hypokinetic cardiomyopathy); Chest wall pain; Death NOS; Dysphasia; Ejection fraction decreased; Gastroesophageal reflux disease; Gastrointestinal pain; General disorders and administration site conditions - Other (general physical health deterioration);
  • Volume 7S (2007)

    Volume 7S (2007)

    Volume 7S (2007) AMSTERDAM • BOSTON • JENA • LONDON • NEW YORK • OXFORD • PARIS • PHILADELPHIA • SAN DIEGO • ST. LOUIS The official journal of the Mitochondria Research Society Affiliated with the Japanese Society of Mitochondrial Research and Medicine Editor-in-Chief: K.K. Singh, Mitochondrion Editorial Office, BLSC, L3-316, Department of Cancer Genetics, Roswell Park Cancer Institute, Elm and Carlton, Buffalo, NY 14263, USA. E-mail: [email protected] Honorary Editors: B. Chance, Philadelphia, PA, USA R. Luft, Stockholm, Sweden A.W. Linnane, Melbourne, Australia P.P. Slonimski, Gif sur Yvette, France Associate Editors: G. Attardi, Pasadena, CA, USA H.J. Majima, Kagoshima, Japan R.A. Butow, Dallas, TX, USA J.A. Morgan-Hughes, London, UK D. Clayton, Stanford, CA, USA R. Naviaux, San Diego, CA, USA K.J.A. Davies, Los Angeles, CA, USA S. Ohta, Kanagawa, Japan A.D.N.J. de Grey, Cambridge, UK J. Reed, La Jolla, CA, USA L. Grivell, Amsterdam, The Netherlands I. Reynolds, Pittsburgh, PA, USA Y. Goto, Tokyo, Japan M. Tanaka, Tokyo, Japan O. Hurko, Collegeville, PA, USA A.A. Tzagoloff, New York, NY, USA N. Ishii, Kanagawa, Japan D. Wallace, Irvine, CA, USA R. Jansen, Sydney, Australia D.R. Wolstenhome, Salt Lake City, UT, USA G. Kroemer, Villejuif, France S. Zullo, Gaithersburg, MD, USA K. Kita, Tokyo, Japan Assistant Editors: V. Bohr, Baltimore, MD, USA C. Moraes, Miami, FL, USA G. Clark-Walker, Canberra, Australia P. Nagley, Clayton, Australia G. Cortopassi, Davis, CA, USA A.-L. Neiminen, Cleveland, OH, USA G. Fiskum, Baltimore, MD, USA G. Paradies, Bari, Italy M. Gerschenson, Honolulu, HI, USA P.
  • Fake News Vs. Healthy Diet

    Fake News Vs. Healthy Diet

    Fake News vs. Healthy Diet Catarina Mafalda Barreiro Pestana de Vasconcelos Dissertation submitted as partial requirement to obtain the degree of Master in Business Administration Advisor: Prof. Dr. Renato Lopes da Costa, ISCTE Business School, Marketing, Operations and General Management Department September, 2019 Fake News vs Healthy Diet Acknowledgements Foremost, I would like to express my sincere gratitude to my advisor, Professor Dr. Renato Costa, for his unconditional support and help during this thesis dissertation. His guidance was critical for the success of this journey, and I feel very honored to have received his valuable and experienced recommendations, furthermore Professor Dr. Renato Lopes da Costa was al- ways ready to help and patiently guided me throughout the thesis. I would also like to show my gratitude, to Dr. Lídia Tarré, Administrator at Gelpeixe, who suggested, during my master’s degree, the implementation of an academic work in her com- pany, which gave way to the theme of this thesis dissertation. Additionally, I need to thank Dr. Lídia Tarré, for introducing me to my advisor, Professor Dr. Renato Lopes da Costa. My sincere thanks also go to the nutritionist Filipa Abreu, who very diligently clarified all my technical uncertainties and a critical help during the interviews process. I am very grateful to my aunt, Dr. Joana Vasconcellos, who helped me with the language re- view. Despite holding an advanced certificate in English, English is not my mother tongue. Hence my aunt, for whom English is the second language, gave me a useful hand with the language challenge. Last, but not least, a deep thank you goes to my family, for all the support, inspiration and understanding during the master’s degree and thesis dissertation.
  • IAEA Laboratory Activities

    IAEA Laboratory Activities

    TECHNICAL REPORTS SERIES No. 90 IAEA Laboratory Activities THE IAEA LABORATORIES AT VIENNA AND SEIBERSDORF THE INTERNATIONAL LABORATORY OF MARINE RADIOACTIVITY AT MONACO THE INTERNATIONAL CENTRE FOR THEORETICAL PHYSICS. TRIESTE THE MIDDLE EASTERN REGIONAL RADIOISOTOPE CENTRE FOR THE ARAB COUNTRIES, CAIRO FIFTH REPORT i j INTERNATIONAL ATOMIC ENERGY AGENCY,VIENNA, 1968 IAEA LABORATORY ACTIVITIES Fifth Report The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GERMANY, FEDERAL NORWAY ALBANIA REPUBLIC OF PAKISTAN ALGERIA GHANA PANAMA ARGENTINA GREECE PARAGUAY AUSTRALIA GUATEMALA PERU AUSTRIA HAITI PHILIPPINES BELGIUM HOLY SEE POLAND BOLIVIA HUNGARY PORTUGAL BRAZIL ICELAND ROMANIA BULGARIA INDIA SAUDI ARABIA BURMA INDONESIA SENEGAL BYELORUSSIAN SOVIET IRAN SIERRA LEONE SOCIALIST REPUBLIC IRAQ SINGAPORE CAMBODIA ISRAEL SOUTH AFRICA CAMEROON ITALY SPAIN CANADA IVORY COAST SUDAN CEYLON JAMAICA SWEDEN CHILE JAPAN SWITZERLAND CHINA JORDAN SYRIAN ARAB REPUBLIC COLOMBIA KENYA THAILAND CONGO, DEMOCRATIC KOREA, REPUBLIC OF TUNISIA REPUBLIC OF KUWAIT TURKEY COSTA RICA LEBANON UGANDA CUBA LIBERIA UKRAINIAN SOVIET SOCIALIST CYPRUS LIBYA REPUBLIC CZECHOSLOVAK SOCIALIST LUXEMBOURG UNION OF SOVIET SOCIALIST REPUBLIC MADAGASCAR REPUBLICS DENMARK MALI UNITED ARAB REPUBLIC DOMINICAN REPUBLIC MEXICO UNITED KINGDOM OF GREAT ECUADOR MONACO BRITAIN AND NORTHERN EL SALVADOR MOROCCO IRELAND ETHIOPIA NETHERLANDS UNITED STATES OF AMERICA FINLAND NEW ZEALAND URUGUAY FRANCE NICARAGUA VENEZUELA GABON NIGERIA VIET-NAM YUGOSLAVIA The Agency's Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters, New York; it entered into force on 29 July 1957. The Headquarters of the Agency are situated in Vienna. Its principal objective is "to accelerate and enlarge the contribution of atomic energy to peace, health and prosperity throughout the world".